The historical rank and industry rank for GlaxoSmithKline Consumer Nigeria's EV-to-FCF or its related term are showing as below:
NSA:GLAXOSMITH'
s EV-to-FCF Range Over the Past 10 Years
Min: -1060.29 Med: -4.37 Max: 201.36
Current: 0.33
During the past 13 years, the highest EV-to-FCF of GlaxoSmithKline Consumer Nigeria was 201.36. The lowest was -1060.29. And the median was -4.37.
NSA:GLAXOSMITH's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 24.52
vs NSA:GLAXOSMITH: 0.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GlaxoSmithKline Consumer Nigeria's EV-to-FCF
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Consumer Nigeria's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's EV-to-FCF falls into.
GlaxoSmithKline Consumer Nigeria's current Enterprise Value is ₦2,329 Mil.
GlaxoSmithKline Consumer Nigeria's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦7,108 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
GlaxoSmithKline Consumer Nigeria's PE Ratio for today is calculated as:
GlaxoSmithKline Consumer Nigeria's share price for today is ₦17.00.
GlaxoSmithKline Consumer Nigeria's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦0.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GlaxoSmithKline Consumer Nigeria EV-to-FCF Related Terms
Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSA:GLAXOSMITH has been successfully added to your 